Quarterly report pursuant to Section 13 or 15(d)

Segments (Details)

v3.2.0.727
Segments (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Dec. 31, 2014
Segment Reporting Information [Line Items]          
Lymphoseek sales revenue $ 1,963,548 $ 1,046,257 $ 3,798,970 $ 1,672,888  
Lymphoseek license revenue 250,000 0 333,333 0  
Grant and other revenue 654,360 28,433 844,061 153,606  
Total revenue 2,867,908 1,074,690 4,976,364 1,826,494  
Cost of goods sold 332,730 270,498 781,787 463,718  
Research and development expenses 2,297,074 5,112,098 6,278,362 10,338,892  
Selling, general and administrative expenses, excluding depreciation and amortization2 3,934,898   9,314,905    
Depreciation and amortization 149,347   299,139 235,356  
Loss from operations (3,810,695) (9,215,558) (11,626,752) (17,794,601)  
Other income (expense), excluding equity in the loss of R-NAV, LLC (5,874,019)   (5,086,960)    
Equity in the loss of R-NAV, LLC (6,205) 0 (268,432) 0  
Net loss (9,690,919) $ (10,222,234) (16,982,144) (21,962,787)  
Total assets, net of depreciation and amortization: 22,198,589   22,198,589   $ 11,830,308
Payments to Acquire Property, Plant, and Equipment 27,618   27,618 $ 1,108,164  
United States          
Segment Reporting Information [Line Items]          
Lymphoseek sales revenue 1,963,273   3,793,920    
Total assets, net of depreciation and amortization: 21,726,705   21,726,705    
International          
Segment Reporting Information [Line Items]          
Lymphoseek sales revenue 275   5,050    
Total assets, net of depreciation and amortization: 471,884   471,884    
Diagnostics          
Segment Reporting Information [Line Items]          
Lymphoseek license revenue 250,000   333,333    
Grant and other revenue 654,360   844,061    
Total revenue 2,867,908   4,976,364    
Cost of goods sold 332,730   781,787    
Research and development expenses 2,120,336   6,015,610    
Selling, general and administrative expenses, excluding depreciation and amortization2 1,529,042   3,571,217    
Depreciation and amortization 72,289   144,397    
Loss from operations (1,151,043)   (5,465,571)    
Other income (expense), excluding equity in the loss of R-NAV, LLC 0   0    
Equity in the loss of R-NAV, LLC 0   0    
Net loss (1,151,043)   (5,465,571)    
Payments to Acquire Property, Plant, and Equipment 25,492   25,492    
Diagnostics | United States          
Segment Reporting Information [Line Items]          
Lymphoseek sales revenue 1,963,273   3,793,920    
Total assets, net of depreciation and amortization: 4,035,926   4,035,926    
Diagnostics | International          
Segment Reporting Information [Line Items]          
Lymphoseek sales revenue 275   5,050    
Total assets, net of depreciation and amortization: 470,033   470,033    
Therapeutics          
Segment Reporting Information [Line Items]          
Lymphoseek license revenue 0   0    
Grant and other revenue 0   0    
Total revenue 0   0    
Cost of goods sold 0   0    
Research and development expenses 176,738   262,752    
Selling, general and administrative expenses, excluding depreciation and amortization2 64,018   78,384    
Depreciation and amortization 0   0    
Loss from operations (240,756)   (341,136)    
Other income (expense), excluding equity in the loss of R-NAV, LLC 0   0    
Equity in the loss of R-NAV, LLC 0   0    
Net loss (240,756)   (341,136)    
Payments to Acquire Property, Plant, and Equipment 0   0    
Therapeutics | United States          
Segment Reporting Information [Line Items]          
Lymphoseek sales revenue 0   0    
Total assets, net of depreciation and amortization: 0   0    
Therapeutics | International          
Segment Reporting Information [Line Items]          
Lymphoseek sales revenue 0   0    
Total assets, net of depreciation and amortization: 0   0    
Corporate          
Segment Reporting Information [Line Items]          
Lymphoseek license revenue 0   0    
Grant and other revenue 0   0    
Total revenue 0   0    
Cost of goods sold 0   0    
Research and development expenses 0   0    
Selling, general and administrative expenses, excluding depreciation and amortization2 2,341,838   5,665,304    
Depreciation and amortization 77,058   154,742    
Loss from operations (2,418,896)   (5,820,045)    
Other income (expense), excluding equity in the loss of R-NAV, LLC (5,874,019)   (5,086,960)    
Equity in the loss of R-NAV, LLC (6,205)   (268,432)    
Net loss (8,299,120)   (11,175,437)    
Payments to Acquire Property, Plant, and Equipment 2,126   2,126    
Corporate | United States          
Segment Reporting Information [Line Items]          
Lymphoseek sales revenue 0   0    
Total assets, net of depreciation and amortization: 17,690,779   17,690,779    
Corporate | International          
Segment Reporting Information [Line Items]          
Lymphoseek sales revenue 0   0    
Total assets, net of depreciation and amortization: $ 1,851   $ 1,851